GenScript, Singapore's EDDC partner on antifibrosis antibody development

By The Science Advisory Board staff writers

April 21, 2021 -- GenScript ProBio is collaborating with the Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, on an antifibrosis antibody to treat idiopathic pulmonary fibrosis.

Both organizations will use next-generation technologies to accelerate the development of therapeutics. They will combine EDDC's high-throughput single B-cell cloning and recombinant antibody generation platform with GenScript ProBio's antibody drug discovery capacities including single B cell, phage display, hybridoma, fully human, and bispecific antibody technologies.

Financial details of the collaboration were not disclosed. GenScript ProBio is the contract development and manufacturing organization segment of GenScript Biotech.

GenScript supports InnoBation's development of CAR T therapies
GenScript Biotech has signed an agreement with InnoBation for cell line development and engineering and manufacturing services for InnoBation's good manufacturing...
Optofluidics technology accelerates discovery of COVID-19 treatments
Known for its transformative technology, Berkeley Lights is a pioneer in optofluidics, which has supported the biopharmaceutical industry for years with...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter